Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile
Articles by Roxana Dronca
Mayo Clinic Q&A: Will at-home cancer care become a possibility?
DEAR MAYO CLINIC: I was my mom’s caregiver as she navigated cancer treatment. Traveling from one appointment to another, we both wondered if some of the care could have been done at home. Is that being considered? ANSWER: As you and your mom have experienced, cancer is a life-altering diagnosis requiring complex care.
Advancing Prostate Cancer Survivorship Through Transatlantic Consortium Science: The iCCaRE Initiative.
Black/African American populations, globally, bear the greatest prostate cancer (CaP) burden compared to other racial/ethnic groups. Addressing CaP disparities in Black men is complex, requiring a patient-centered, community-centric and comprehensive approach. This study integrates iCCaRE Consortium findings and broader literature to address unmet needs in survivorship care.
Subcutaneous Immuno-Oncology Options Available for Metastatic Melanoma
Dronca (00:11): Good evening, everyone. Welcome to chapter 2 of our discussion today. The topic is subcutaneous immunotherapy options for patients with melanoma. And wanted to start by really introducing the 2 options that we have now for patients that are relevant to patients with melanoma, 2 subcutaneous options that were recently approved. And those are nivolumab and hyaluronidase and pembrolizumab and berahyaluronidase.
Advantages of Subcutaneous Immuno-Oncology for Patients
Dronca (00:11): Good evening, everyone. Thank you for joining us on our next topic, advantages of subcutaneous immunotherapy for patients. As we have discussed previously and based on the recent data, we appreciate that one of the strongest patient-level advantage for subcutaneous immunotherapy is that it reduces one of the maybe least appreciated burdens for patients, and that is the time spent receiving treatment.
How to Implement Subcutaneous Immuno-Oncology for Providers
Dronca (00:12): Good evening, everyone. Thank you for joining us for our chapter on how to implement subcutaneous immunotherapy options for providers, even when clinicians recognize the value of the option implementation can falter when practices lack a clear path to operationalize it. So with this, I'm going to invite my colleagues to comment on how can we operationalize in a way that preserves clinic workflow and minimizes disruption. Jen, would you like to comment? Hunze (00:46): Great.
Standard Immuno-Oncology Options for the Melanoma Landscape and Unmet Needs for Patients
Roxana Dronca, MD (00:11): Thank you for joining us. Our session is “Subcutaneous Immuno-Oncology for Metastatic Melanoma, Clinical Contacts, Patient Value and Practice Implementation.” My name is Roxana Dronca. I'm a medical oncologist. I practice at Mayo Clinic in Jacksonville, Florida. My area of expertise is cutaneous oncology.
Will at-home cancer care become a possibility?
DEAR MAYO CLINIC: I was my mom’s caregiver as she navigated cancer treatment. Traveling from one appointment to another, we both wondered if some of the care could have been done at home. Is that being considered? ANSWER: As you and your mom have experienced, cancer is a life-altering diagnosis requiring complex care.
Will at-home cancer care become a possibility? - Tribune Content Agency
DEAR MAYO CLINIC: I was my mom’s caregiver as she navigated cancer treatment. Traveling from one appointment to another, we both wondered if some of the care could have been done at home. Is that being considered? ANSWER: As you and your mom have experienced, cancer is a life-altering diagnosis requiring complex care.
Oncologists Urged to Discuss Fertility With Patients, as ASCO Updates Guidelines
This transcript has been lightly edited for clarity. Robert A. Figlin, MD: Hello, this is Bob Figlin, the Steven Spielberg Family Chair at Cedar Sinai Cancer and the director of Cedars Sinai Cancer in Los Angeles. I am delighted to have Allison Loren here today. Allison is chief of the Division of Hematology Oncology, director of Blood and Bone Marrow Transplantation, and the C. Willard Robinson Professor of Hematology-Oncology at Penn Medicine. Allison, thank you for joining us today.
Guide Offers Oncologists a Road Map for Cancer-Related Cognitive Impairment
A new at-a-glance flow chart is giving oncologists a simple, actionable screening tool to identify and address cancer-related cognitive impairment (CRCI), a syndrome that can cause significant distress for patients when completing simple daily tasks. Published in JCO Oncology Practice, the guide aims to make CRCI more visible and manageable, helping oncologists take early action for a syndrome that is often overlooked.
Oncology’s Utilization Management Problem: Do We Already Have an Answer?
Editor’s Note: This is part of an ongoing series designed for oncologists to share their opinions on key issues. If you would like to submit a commentary for consideration, please contact us. I had just finished seeing my last patient of the day and was busy tying up loose ends in my oncology clinic – running through my inbox, answering quick questions from a palliative care colleague, and checking in on the status of the infusion room – when I got a ping from our prior authorization coordinator.
A “Revolution” in the Making: Subcutaneous Drugs Are Changing Cancer Care
The conversation and transcript have been lightly edited for clarity and length. Roxana S. Dronca, MD: Good afternoon. Welcome to Oncology News Central. I am Dr. Roxana Dronca. I'm a medical oncologist at Mayo Clinic in Florida. And I'm joined today by some of my amazing colleagues, and we are here to discuss about the future of subcutaneous drugs in oncology. So, I will let my colleagues introduce themselves and I'll start maybe with you, Deb. Deborah Fischer, PA-C: Hi, my name is Deborah Fisher.
Challenges and Strategies: Subcutaneous Drugs Will Drive Practice Changes
The conversation and transcript have been lightly edited for clarity and length. Jennifer Hunze, RN: Welcome to Oncology News Central. My name is Jennifer Hunze. I am a registered nurse at Mayo Clinic. I'm here with a team of experts regarding oncology care, and we're going to talk specifically about subcutaneous (sub-Q) injection of some of our oncologic medications. I'm going to let the speakers introduce themselves. Lucia? Lucia Nolan, PharmD: Hey, my name is Lucia Nolan.
Will Subcutaneous Cancer Drugs Be a Gamechanger?
This transcript has been lightly edited for clarity and length. Roxana S. Dronca, MD: Good afternoon. We're here for Oncology News Central. I am Dr. Roxana Dronca. I am a medical oncologist. I practice at Mayo Clinic in Jacksonville. My specialty is skin cutaneous oncology and GU malignancies. And I am here with my team, my wonderful colleagues to discuss the topic of subcutaneous drugs in oncology and I will let them introduce themselves. Jennifer? Jennifer Hunze, RN: Hi, I'm Jennifer Hunze.
Survival Up With Nivolumab + Ipilimumab Versus Chemo for Metastatic CRC
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Personalized Starting Age of Gastric Cancer Screening Based on the Individual Risk Profile
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Olaparib and Temozolomide in Patients With SCLC: Final Analysis and CNS Outcomes
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Neoadjuvant Chemoradiation Followed by FOLFIRINOX for Stage II/III Rectal Cancer
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Real-World Outcomes in Patients With Brain Metastases Secondary to HR+/HER2− MBC Treated With Abemaciclib and Local Intracranial Therapy
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Adding Pembrolizumab Ups Survival in Stage III Undifferentiated Sarcoma
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Half of Young Cancer Patients Report Fertility Preservation Discussion With Provider
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Azacitidine Plus Shortened Venetoclax Treatment Cycles for AML
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Pathological Response Following Neoadjuvant Immune Checkpoint Inhibitors in Patients With Hepatocellular Carcinoma
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
HLA Mismatching and Survival After Contemporary HCT in Patients With Hematologic Malignancies
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Restaging MRI Can Predict Survival With Rectal Cancer
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Medicaid Expansion Increases Guideline-Concordant Treatment for Breast Cancer
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Impact of Dexamethasone Dose Reduction During Induction Therapy in Patients With Newly Diagnosed Multiple Myeloma
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Outcomes of Pembrolizumab Plus Chemotherapy in Asian Patients With Advanced TNBC
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
15-Gene Expression Profile and PRAME as an Integrated Prognostic Test for Uveal Melanoma
Disclosures Article Citation Journal of Clinical Oncology From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Excess Adiposity Plays Role in Postmenopausal HR-Positive Breast Cancer
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
KEYNOTE-006: Advanced Stage IV or Unresectable Stage III Melanoma - 10-Year Follow-Up Data
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Venetoclax Plus Decitabine as a Bridge to Allogeneic HSCT in Older Patients With AML
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
One-Dose HPV Vaccination Averts Similar Number of Cancers as Two Doses
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
ASTRO: Hypofractionated Radiation Therapy Safe After Breast Reconstruction
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Prophylactic Efficacy of Olanzapine-Based Therapy for Trastuzumab Deruxtecan-Associated Nausea and Vomiting in Patients With HER2-Positive or HER2-Low Breast Cancer | PracticeUpdate
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Upward Trends in Breast Cancer Incidence Continuing Among Women
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Neoadjuvant Nivolumab and Relatlimab for Locally Advanced MMR-Deficient Colon Cancer
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Dual Functionality of Tocilizumab as a Treatment for ICI-Associated Arthritis and as a Prophylactic Agent During ICI Rechallenge
Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes We have detected that you are using an Ad Blocker. PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
Subcutaneous vs Intravenous Nivolumab for Renal Cell Carcinoma: CheckMate 67T
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Tivozanib Has Efficacy in Advanced Renal Cell Carcinoma Post-ICI Therapy
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
R-MPV Plus Escalating Doses of Lenalidomide or Ibrutinib for Newly Diagnosed Primary CNS Lymphoma
Journal of Hematology & Oncology Phase IB part of LOC-R01, a LOC network non-comparative randomized phase IB/II study testing R-MPV in combination with escalating doses of lenalidomide or ibrutinib for newly diagnosed primary central nervous system lymphoma (PCNSL) patients From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Overtreatment of Prostate Cancer Increasing in Men With Short Life Expectancy
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
Lasting Reduction in Toxicity Seen for MRI-Guided SBRT for Prostate Cancer
Open GPT Console Open Oracle Keywords Refresh Values Property Value Status Version Ad File Disable Ads Flag Environment Moat Init Moat Ready Contextual Ready Contextual URL Contextual Initial Segments Contextual Used Segments AdUnit SubAdUnit Custom Targeting Ad Events Invalid Ad Sizes center of excellence alarm bookmark calendar check-clipboard clockwise compass-navigate compass counterclockwise delete download-book education-history email get-help gizmo-flag help-icon journal left link lock...
BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma
Melanoma patients who responded to anti-PD-1 therapy show an increased levels of a protein (bim) in their tumor-reactive immune cells (T lymphocytes).
BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma
Citation Posted online on October 27, 2016. (doi:10.2217/imt-2016-0100) EditorialBCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanomaRoxana S Dronca??1, Aaron S Mansfield??1, Sean S Park??2 & Haidong Dong??*,3,4 Users who read this article also read:
Bim identifies tumor-reactive effector CD8+ T cells in cancer patients respond to anti-PD-1 therapy
Endogenous tumor-reactive CD8+ T cell responses to tumors are controlled by immune checkpoints. Immune checkpoint blockade strategy has demonstrated therapeutic effects in some solid cancers. However, only a portion of patients responds to this therapy and there are no biomarkers to help predict and monitor treatment outcomes. We report that Bim is a downstream signaling molecule of the PD-1 pathway that reflects the degree of PD-1 interaction with its ligand B7-H1.
Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab
Presented at the 50th Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 30-June 3, 2014; Society for Immunotherapy of Cancer 2014 Annual Meeting & Associated Programs, National Harbor, MD, November 6-9, 2014; and 51st Annual Meeting of the American Society of Clinical Oncology, Chicago, IL, May 29-June 2, 2015.
T cell Bim levels reflect responses to anti-PD-1 cancer therapy
Bim is a PD-1 downstream signaling molecule in tumor-reactive CD8+ T cells. We previously demonstrated that the ligand of PD-1, PD-L1, is responsible for the upregulation of Bim in activated CD8+ T cells in vivo (18). To further investigate whether PD-1 is directly involved in Bim upregulation in tumor-reactive CD8+ T cells, we isolated tumor-infiltrating lymphocytes (TILs) and measured the expression of Bim in PD-1+ tumor-reactive CD8+ T cells identified by their high expression of CD11a (20).
Expert Oncology Information
Show More
loading
Actions
Is this you?
As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.Get in touch with Roxana
Contact Roxana, search articles and posts on X, monitor coverage, and track replies from one place.
Learn more about Muck Rack